Current Evidence for Dosing Romiplostim in Chemotherapy-Induced Thrombocytopenia (CIT)

Romiplostim is a thrombopoietin receptor agonist primarily approved for immune thrombocytopenia (ITP). Its use in chemotherapy-induced thrombocytopenia (CIT) is off-label but increasingly studied due to its potential to stimulate platelet production and reduce chemotherapy delays.

Summary of Current Evidence

• Dosing regimens: Several small studies and case series suggest initial dosing ranging from 1 to 3 µg/kg subcutaneously once weekly.
• Titration: Dose adjustments are made based on platelet response, typically increasing by increments of 1 to 2 µg/kg weekly up to a maximum of approximately 10 µg/kg, aiming for platelet counts sufficient to avoid chemotherapy delays (usually >50,000/µL).
• Timing: Romiplostim is generally started either after the nadir of platelet count post-chemotherapy or preemptively in subsequent cycles to maintain platelet counts.
• Clinical outcomes: Evidence from pilot studies and retrospective cohorts indicates improved platelet recovery, fewer chemotherapy dose reductions/delays, and decreased bleeding risk.
• Safety: Romiplostim was generally well tolerated; however, thrombotic risk and marrow fibrosis remain considerations, necessitating careful monitoring.

Selected Studies

• Ghanima et al., 2017 conducted a phase II study using romiplostim 3 µg/kg weekly in patients with solid tumors and CIT, demonstrating increased platelet counts allowing chemotherapy continuation.
• Li et al., 2020 reported a retrospective analysis with starting doses of 1 µg/kg escalating to 5 µg/kg weekly, showing effective platelet recovery in lymphoma patients.
• Freyer et al., 2019 emphasized individualized dosing with weekly monitoring, noting some patients needed doses above 5 µg/kg for adequate response.

Clinical Considerations

• Romiplostim dosing in CIT is not standardized; treatment should be individualized based on platelet counts and chemotherapy schedule.
• Frequent platelet monitoring (weekly or more) is necessary to guide dosing and avoid excessive thrombocytosis.
• Large randomized controlled trials are still needed to define optimal dosing protocols and long-term safety in CIT.

Conclusion

Current evidence for romiplostim dosing in chemotherapy-induced thrombocytopenia primarily derives from small studies and case series, suggesting starting doses of 1–3 µg/kg weekly with titration based on platelet response. While promising, romiplostim use in CIT remains off-label, and more robust clinical trials are needed to establish standardized dosing guidelines.

Use of GLP-1 Receptor Agonists in Patients with Quadriplegia or Neurogenic Bowel

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in the management of type 2 diabetes and obesity due to their effects on glucose regulation and weight loss. However, data specifically addressing their use in patients with quadriplegia or neurogenic bowel are limited.

Available Evidence and Considerations

• Scarcity of Direct Studies: There are no large clinical trials or extensive studies specifically examining the safety and efficacy of GLP-1 RAs in patients with quadriplegia or neurogenic bowel dysfunction. Most information is extrapolated from broader populations.
• Gastrointestinal Effects: GLP-1 RAs slow gastric emptying and can cause gastrointestinal side effects such as nausea, vomiting, and constipation. In patients with neurogenic bowel, who often have impaired gut motility, these effects could potentially exacerbate bowel dysfunction.
• Potential Benefits: Because patients with spinal cord injury often have increased risk for metabolic syndrome, type 2 diabetes, and obesity, GLP-1 RAs might offer metabolic benefits. However, clinical judgment is necessary to balance benefits with risks related to bowel and autonomic dysfunction.
• Case Reports and Expert Opinions: Some case reports and expert opinion pieces suggest cautious use with close monitoring of gastrointestinal symptoms in this population.
• Consultation Recommended: It is advisable for clinicians to work closely with specialists in spinal cord injury and gastroenterology when initiating GLP-1 RAs in these patients.

Summary

Currently, no robust clinical data specifically guide the use of GLP-1 receptor agonists in patients with quadriplegia or neurogenic bowel. Use of these agents should be individualized, considering potential gastrointestinal side effects and altered gut motility. Monitoring for worsening bowel symptoms is important.

References

• Bauman WA, Spungen AM. Metabolic changes in persons after spinal cord injury. Phys Med Rehabil Clin N Am. 2012 Feb;23(1):97-114.
• Jeong SJ, Jee S. Gastrointestinal and metabolic considerations after spinal cord injury. J Neurogastroenterol Motil. 2014 Jul;20(3):360-9.
• Davani B, et al. GLP-1 receptor agonists in diabetic patients with gastrointestinal motility disorders: a review. Diabetes Ther. 2021;12(5):1243-1258.
• American Diabetes Association. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2024. Diabetes Care. 2024 Jan;47(Supplement 1):S98-S110.

Venofer Skin Staining: Infusion vs. IV Push

Is there a difference or increased risk of skin staining with Venofer administration methods?

Venofer (iron sucrose) is commonly administered either as a slow intravenous (IV) infusion or as an IV push/injection. Skin staining typically results from extravasation (leakage) of the iron preparation into surrounding tissues during administration.

The risk of skin staining is generally related to extravasation rather than the method of administration itself. However:

• IV push: Because it is administered as a rapid injection, there may be a slightly higher risk of vein irritation or infiltration, which could increase the chance of extravasation if the catheter is not properly positioned.
• IV infusion: Usually administered more slowly over 15–30 minutes, allowing better monitoring of the infusion site for signs of infiltration, potentially reducing the likelihood of extravasation.

Therefore, while the risk of staining exists with both methods, a slow infusion may reduce the risk by providing more opportunity to detect and correct infiltration early.

Patient populations more likely to experience skin staining

Certain patient factors may increase the risk of extravasation and subsequent skin staining:

• Patients with fragile or small veins: Elderly patients, pediatric patients, or those with compromised venous access.
• Patients with poor peripheral circulation.
• Patients with prior multiple IV sites or scarring: Increasing the difficulty of IV placement.
• Patients requiring frequent IV iron treatments: Repeated exposures may increase cumulative risk.

Summary

- Skin staining results primarily from extravasation of Venofer, regardless of whether given by infusion or IV push.
- Slower infusion allows for better monitoring and may reduce risk.
- Patient factors such as vein quality and circulation influence extravasation risk.
- Proper IV technique and site monitoring are critical to minimize staining risk.

References on the Impact of Discharge Medication History and Reconciliation on Readmissions

• Coleman, E. A., Parry, C., Chalmers, S., & Min, S. J. (2006). The care transitions intervention: Results of a randomized controlled trial. Archives of Internal Medicine, 166(17), 1822–1828.
  https://doi.org/10.1001/archinte.166.17.1822
• Kripalani, S., Jackson, A. T., Schnipper, J. L., & Coleman, E. A. (2007). Promoting effective transitions of care at hospital discharge: A review of key issues for hospitalists. Journal of Hospital Medicine, 2(5), 314–323.
  https://doi.org/10.1002/jhm.228
• Mueller, S. K., Sponsler, K. C., Kripalani, S., & Schnipper, J. L. (2012). Hospital-based medication reconciliation practices: A systematic review. Archives of Internal Medicine, 172(14), 1057–1069.
  https://doi.org/10.1001/archinternmed.2012.2797
• Gleason, K. M., McDaniel, M. R., Feinglass, J., et al. (2010). Results of the Medications at Transitions and Clinical Handoffs (MATCH) study: An analysis of medication reconciliation errors and risk factors at hospital admission. Journal of General Internal Medicine, 25(5), 441–447.
  https://doi.org/10.1007/s11606-009-1189-z
• Forster, A. J., Murff, H. J., Peterson, J. F., Gandhi, T. K., & Bates, D. W. (2003). The incidence and severity of adverse events affecting patients after discharge from the hospital. Annals of Internal Medicine, 138(3), 161–167.
  https://doi.org/10.7326/0003-4819-138-3-200302040-00007

Optimal Administration of IV Iron Sucrose in Pediatric and Adolescent Patients

1. Maximum Dose per Infusion

To minimize adverse reactions, the commonly recommended maximum dose of IV iron sucrose per infusion in pediatric patients is generally 100–200 mg per session. Some protocols suggest doses up to 7 mg/kg per infusion, not exceeding 200 mg at once.

2. Concentration and Rate of Administration

- Concentration: IV iron sucrose is typically diluted to a concentration of approximately 1–2 mg/mL in 0.9% sodium chloride.
- Rate: Administration should be given as a slow intravenous infusion over at least 15 to 30 minutes. For smaller doses or younger children, infusion times may be proportionally longer to reduce risk of infusion reactions.

3. Pre-medications

Routine pre-medications are generally not recommended unless the patient has a history of allergic reactions or previous intolerance to IV iron products.

• If pre-medication is considered, antihistamines (e.g., diphenhydramine) or corticosteroids may be administered, but these can themselves cause side effects and are not routinely used.
• Premedication decisions should be individualized based on clinical history.

4. Monitoring Post-infusion

Patients should be monitored closely for adverse reactions during the infusion and for at least 30 minutes post-infusion to promptly identify and manage potential hypersensitivity or other infusion-related reactions.

Note: Facilities should be equipped to manage anaphylactic reactions, though these are rare.

Summary Table

Additional Considerations

- Always assess patient's iron status, weight, and comorbidities before dosing.
- Ensure emergency medications and equipment are readily available.
- Report any adverse events per institutional protocols.

References

• American Academy of Pediatrics Clinical Report on Pediatric Iron Deficiency (latest guidelines)
• Manufacturer's prescribing information for Venofer (iron sucrose)
• Expert consensus and clinical practice guidelines on IV iron therapy in children